Literature DB >> 3934801

Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations.

B Horowitz, M E Wiebe, A Lippin, M H Stryker.   

Abstract

Use of the organic solvent, tri(n-butyl)phosphate (TNBP), and detergents for the inactivation of viruses in labile blood derivatives was evaluated by addition of marker viruses (VSV, Sindbis, Sendai, EMC) to anti-hemophilic factor (AHF) concentrates. The rate of virus inactivation obtained with TNBP plus Tween 80 was superior to that observed with ethyl ether plus Tween 80, a condition previously shown to inactivate greater than or equal to 10(6.9) CID50 of hepatitis B and greater than or equal to 10(4) CID50 of Hutchinson strain non-A, non-B hepatitis. The AHF recovery after TNBP/Tween treatment was greater than or equal to 90 percent. Following the reaction, TNBP could be removed from the protein by gel exclusion chromatography on Sephadex G25; however, because of its large micelle size, Tween 80 could not be removed from protein by this method. Attempts to remove Tween 80 by differential precipitation of protein were only partially successful. An alternate detergent, sodium cholate, when combined with TNBP, resulted in almost as efficient virus inactivation and an 80 percent recovery of AHF. Because sodium cholate forms small micelles, it could be removed by Sephadex G25 chromatography. Electrophoretic examination of TNBP/cholate-treated AHF concentrates revealed few, if any, changes in protein mobility, except for plasma lipoprotein(s).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3934801     DOI: 10.1046/j.1537-2995.1985.25686071422.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  33 in total

1.  A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies.

Authors:  Melvin Berger
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

2.  No evidence for neoantigens in human plasma after photochemical virus inactivation.

Authors:  H Mohr; J Knüver-Hopf; B Lambrecht; H Scheidecker; H Schmitt
Journal:  Ann Hematol       Date:  1992-11       Impact factor: 3.673

3.  Respiratory syncytial virus immune globulin intravenous.

Authors: 
Journal:  Paediatr Child Health       Date:  1998-01       Impact factor: 2.253

Review 4.  Blood transfusion and hepatitis: still a threat?

Authors:  H W Reesink; C L van der Poel
Journal:  Blut       Date:  1989-01

5.  Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

Review 6.  Ultrapure plasma factor VIII produced by anti-F VIII c immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human).

Authors:  M Griffith
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

Review 7.  Safety of blood transfusion: the Japanese experience.

Authors:  H Ikeda
Journal:  Can J Anaesth       Date:  1991-07       Impact factor: 5.063

8.  Effective virus inactivation and removal by steps of Biotest Pharmaceuticals IGIV production process.

Authors:  Herbert O Dichtelmüller; Eckhard Flechsig; Frank Sananes; Michael Kretschmar; Christopher J Dougherty
Journal:  Results Immunol       Date:  2012-01-16

9.  Photo-induced inactivation of viruses: adsorption of methylene blue, thionine, and thiopyronine on Qbeta bacteriophage.

Authors:  S Jockusch; D Lee; N J Turro; E F Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 10.  Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.

Authors:  Jeanne M Lusher; Inge Scharrer
Journal:  Int J Hematol       Date:  2009-11-03       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.